HCC in metabolic syndrome: current concepts and future directions

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally. In recent years, the metabolic syndrome epidemic is changing the etiological landscape of HCC, with metabolic liver disease comprising an exponentially increasing proportion of HCC cases. In this review, we discuss HCC in the context of metabolic syndrome, including its epidemiology, its unique clinical and pathological characteristics, and its multifactorial pathogenesis. We also discuss HCC prevention and management as relates to these patients.

Keywords

Hepatocellular carcinoma / metabolic syndrome / non-alcoholic fatty liver disease / non-alcoholic steatohepatitis / metabolic associated fatty liver disease / PNPLA3 / HSD17B13 / sorafenib / steatosis

References

[1] Association for the Study of the Liver; Electronic address: [e-mail]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[2] Liu Z,Yuan H.The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention.J Hepatol2019;70:674-83

[3] Noureddin M.Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.Clin Liver Dis2015;19:361-79 PMCID:PMC6658171

[4] Huang PL.A comprehensive definition for metabolic syndrome.Dis Model Mech2009;2:231-7 PMCID:PMC2675814

[5] Eckel RH,Zimmet PZ.The metabolic syndrome.Lancet2005;365:1415-28

[6] Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402

[7] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8

[8] Day CP.Steatohepatitis: a tale of two “hits”?.Gastroenterology1998;114:842-5

[9] Tilg H.Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.Hepatology2010;52:1836-46

[10] Eslam M,George J.International Consensus PanelMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[11] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[12] Younossi ZM,Afendy M.Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.Clin Gastroenterol Hepatol2011;9:524-530.e1; quiz e60

[13] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[14] Foschi FG,Domenicali M.Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study.BMC Gastroenterol2018;18:177 PMCID:PMC6262973

[15] Soresi M,Cefalù AB.Metabolic Syndrome Study GroupNonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society.Acta Diabetol2013;50:241-9

[16] Younossi ZM,Henry L.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.Hepatology2015;62:1723-30

[17] Cho EJ,Jang ES.Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area.Digestion2011;84 Suppl 1:17-22

[18] Myers S,Spahr L.NAFLD and MAFLD as emerging causes of HCC: a populational study.JHEP Rep2021;3:100231 PMCID:PMC7957147

[19] Office fédéral de la statitique. Enquête Suisse Sur La Santé 2017. https://www.bfs.admin.ch/bfs/fr/home/statistiques/sante/determinants/exces-poids.html [Last accessed on 17 Jan 2021]

[20] Younossi Z,Ong JP.Global Nonalcoholic Steatohepatitis CouncilNonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.Clin Gastroenterol Hepatol2019;17:748-755.e3

[21] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[22] Kanwal F,Mapakshi S.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology2018;155:1828-37.e2 PMCID:PMC6279617

[23] Amarapurkar DN,Gautam S.Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis.Trop Gastroenterol2013;34:159-63

[24] Yatsuji S,Tobari M,Tokushige K.Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.J Gastroenterol Hepatol2009;24:248-54

[25] Hsiang JC,Raos Z.Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand.Intern Med J2015;45:160-9

[26] Estes C,Arias-Loste MT.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol2018;69:896-904

[27] Goossens N,Cerny A.Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.Swiss Med Wkly2019;149:w20152

[28] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.Hepatology2018;67:328-57

[29] Kodama K,Hyogo H.Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.J Gastroenterol Hepatol2019;34:1626-32

[30] Mittal S,Sada YH.Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2016;14:124-31.e1 PMCID:PMC4690789

[31] Tokushige K,Nakajima T.Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey.J Gastroenterol2016;51:586-96

[32] Yasui K,Komorizono Y.Japan NASH Study GroupMinistry of HealthLabourand Welfare of JapanCharacteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.Clin Gastroenterol Hepatol2011;9:428-33; quiz e50

[33] Piscaglia F,Barchetti A.HCC-NAFLD Italian Study GroupClinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study.Hepatology2016;63:827-38

[34] Koh YX,Liew YX.Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma.J Am Coll Surg2019;229:467-478.e1

[35] Paradis V,Chelbi E.Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.Hepatology2009;49:851-9

[36] Bengtsson B,Wahlin S,Hagström H.Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.Liver Int2019;39:1098-108

[37] Tobari M,Taniai M.The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.J Gastroenterol Hepatol2020;35:862-9

[38] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.PLoS Med2014;11:e1001624 PMCID:PMC3972088

[39] Yau T,Kim TY.Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial.JAMA Oncol2020;6:e204564 PMCID:PMC7530824

[40] Romeo S,Valenti L.Leveraging Human genetics to identify potential new treatments for fatty liver disease.Cell Metab2020;31:35-45

[41] Trépo E.Update on NAFLD genetics: from new variants to the clinic.J Hepatol2020;72:1196-209

[42] Bianco C,Pelusi S.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol2021;74:775-82 PMCID:PMC7987554

[43] Ioannou GN,Kerr KF.Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.J Hepatol2019;71:523-33 PMCID:PMC6702126

[44] Adler M,Trovato FM,Pasha Y.Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study.HPB (Oxford)2016;18:678-83 PMCID:PMC4972373

[45] Kanwal F.Surveillance for hepatocellular carcinoma: current best practice and future direction.Gastroenterology2019;157:54-64 PMCID:PMC6636644

[46] Fujiwara N,Goossens N.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.J Hepatol2018;68:526-49 PMCID:PMC5818315

[47] Negro F.Natural history of NASH and HCC.Liver Int2020;40 Suppl 1:72-6

[48] Marchesini G,Morselli-labate AM.Association of nonalcoholic fatty liver disease with insulin resistance.Am J Med1999;107:450-5

[49] Sheth SG,Chopra S.Nonalcoholic steatohepatitis.Ann Intern Med1997;126:137-45

[50] Davila JA,Shaib Y,El-Serag HB.Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.Gut2005;54:533-9 PMCID:PMC1774454

[51] Yang JD,Mara KC.Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease.Hepatology2020;71:907-16 PMCID:PMC6960360

[52] Calle EE,Walker-Thurmond K.Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults.N Engl J Med2003;348:1625-38

[53] Park EJ,Yu GY.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.Cell2010;140:197-208 PMCID:PMC2836922

[54] Healy ME,Hargett SR.Dietary sugar intake increases liver tumor incidence in female mice.Sci Rep2016;6:22292 PMCID:PMC4770276

[55] Piguet AC,Simillion C.Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.J Hepatol2015;62:1296-303

[56] Baumeister SE,Aleksandrova K.Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study.J Hepatol2019;70:885-92

[57] Caussy C,Cui J.Familial NAFLD Cirrhosis Research ConsortiumNonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.J Clin Invest2017;127:2697-704 PMCID:PMC5490764

[58] Long MT,Massaro JM.Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring.Liver Int2019;39:740-7 PMCID:PMC6758911

[59] Romeo S,Xing C.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2008;40:1461-5 PMCID:PMC2597056

[60] BasuRay S,Cohen JC.The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation.Hepatology2017;66:1111-24 PMCID:PMC5605398

[61] Mazo DF,Stefano JT.Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.Ann Hepatol2019;18:466-71

[62] Liu YL,Leathart JB.Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.J Hepatol2014;61:75-81

[63] Liu YL,Burt AD.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Nat Commun2014;5:4309 PMCID:PMC4279183

[64] Pelusi S,Pietrelli A.Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease.Sci Rep2019;9:3682 PMCID:PMC6403344

[65] Anstee QM,Kotsiliti E,Heikenwalder M.From NASH to HCC: current concepts and future challenges.Nat Rev Gastroenterol Hepatol2019;16:411-28

[66] Singal AG,Yopp AC.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.Am J Gastroenterol2014;109:325-34 PMCID:PMC5610907

[67] Yang J,Nahon P.PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer2019;144:533-44

[68] Trépo E,Zucman-Rossi J.PNPLA3 gene in liver diseases.J Hepatol2016;65:399-412

[69] Dongiovanni P,Mannisto V.Statin use and non-alcoholic steatohepatitis in at risk individuals.J Hepatol2015;63:705-12

[70] Dongiovanni P,Fares R.PNPLA3 I148M polymorphism and progressive liver disease.World J Gastroenterol2013;19:6969-78 PMCID:PMC3819533

[71] Pirazzi C,Burza MA.Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.J Hepatol2012;57:1276-82

[72] Scorletti E,Bhatia L.Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial.J Hepatol2015;63:1476-83

[73] Liu Z,Zhou L.The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.Sci Rep2017;7:9273 PMCID:PMC5571206

[74] Smagris E,BasuRay S,Hobbs HH.Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins.J Biol Chem2016;291:10659-76 PMCID:PMC4865914

[75] Mahdessian H,Popov S.TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.Proc Natl Acad Sci U S A2014;111:8913-8 PMCID:PMC4066487

[76] Prill S,Baselli G.The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.Sci Rep2019;9:11585 PMCID:PMC6690969

[77] Kim DS,Li YK.Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns.J Lipid Res2017;58:1471-81 PMCID:PMC5496043

[78] Dongiovanni P,Maglio C.Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.Hepatology2015;61:506-14

[79] Pirola CJ.The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis.Hepatology2015;62:1742-56

[80] Donati B,Romeo S.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.Sci Rep2017;7:4492 PMCID:PMC5495751

[81] Tang S,Mei TT.Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis.BMC Cancer2019;19:1128 PMCID:PMC6868855

[82] Buch S,Trépo E.A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.Nat Genet2015;47:1443-8

[83] Mancina RM,Petta S.The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent.Gastroenterology2016;150:1219-1230.e6 PMCID:PMC4844071

[84] Gijón MA,Zarini S,Voelker DR.Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils.J Biol Chem2008;283:30235-45 PMCID:PMC2573059

[85] Johansen A,Musaev D.Mutations in MBOAT7, encoding lysophosphatidylinositol acyltransferase I, lead to intellectual disability accompanied by epilepsy and autistic features.Am J Hum Genet2016;99:912-6 PMCID:PMC5065650

[86] Teo K,Adams L.EU-PNAFLD Investigators, GOLD Consortium. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis.J Hepatol2021;74:20-30 PMCID:PMC7755037

[87] Willer CJ,Jackson AU.Newly identified loci that influence lipid concentrations and risk of coronary artery disease.Nat Genet2008;40:161-9 PMCID:PMC5206900

[88] Beer NL,McCulloch LJ.The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.Hum Mol Genet2009;18:4081-8 PMCID:PMC2758140

[89] Barbara M,Alkhouri N.New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.Hepatobiliary Surg Nutr2018;7:372-81 PMCID:PMC6230844

[90] Raimondo A,Gloyn AL.Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism.Curr Opin Lipidol2015;26:88-95 PMCID:PMC4422901

[91] Kawaguchi T,Mizuno M.Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.PLoS One2018;13:e0185490 PMCID:PMC5791941

[92] Dewey FE,Overton JD.Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.Science2016;354:aaf6814

[93] Abul-Husn NS,Li AH.A protein-truncating HSD17B13 variant and protection from chronic liver disease.N Engl J Med2018;378:1096-106 PMCID:PMC6668033

[94] Yang J,Nahon P.A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease.Hepatology2019;70:231-40

[95] Wang P,Li Y.HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.Eur Rev Med Pharmacol Sci2020;24:8997-9007

[96] Moeller G.Integrated view on 17beta-hydroxysteroid dehydrogenases.Mol Cell Endocrinol2009;301:7-19

[97] Tsachaki M.Subcellular localization and membrane topology of 17β-hydroxysteroid dehydrogenases.Mol Cell Endocrinol2019;489:98-106

[98] Saloniemi T,Strauss L,Poutanen M.The diversity of sex steroid action: novel functions of hydroxysteroid (17β) dehydrogenases as revealed by genetically modified mouse models.J Endocrinol2012;212:27-40

[99] Luci C,Leclère PS,Gual P.Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies.Front Endocrinol (Lausanne)2020;11:597648 PMCID:PMC7771356

[100] Gehrke N.Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?.Gastroenterology2020;158:1929-1947.e6

[101] Cai J,Li H.The role of innate immune cells in nonalcoholic steatohepatitis.Hepatology2019;70:1026-37

[102] Jenne CN.Immune surveillance by the liver.Nat Immunol2013;14:996-1006

[103] Koo SY,Lee CW.Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.Exp Mol Med2020;52:1209-19 PMCID:PMC8080649

[104] Stiglund N,Cornillet M.Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease.Front Immunol2019;10:1255 PMCID:PMC6558016

[105] Narayanan S,Hahn YS.The Immune landscape in nonalcoholic steatohepatitis.Immune Netw2016;16:147-58 PMCID:PMC4917398

[106] Cai L,Zhou L.Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients.Clin Immunol2008;129:428-37

[107] Hoechst B,Ormandy L.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.Hepatology2009;50:799-807 PMCID:PMC6357774

[108] Kubes P.Sterile inflammation in the liver.Gastroenterology2012;143:1158-72

[109] Arrese M,Kalergis AM.Innate immunity and inflammation in NAFLD/NASH.Dig Dis Sci2016;61:1294-303 PMCID:PMC4948286

[110] Szabo G.Inflammasome activation and function in liver disease.Nat Rev Gastroenterol Hepatol2015;12:387-400

[111] Aron-Wisnewsky J,Belda E.Major microbiota dysbiosis in severe obesity: fate after bariatric surgery.Gut2019;68:70-82 PMCID:PMC7143256

[112] Debédat J,Aron-Wisnewsky J.Gut microbiota dysbiosis in human obesity: impact of bariatric surgery.Curr Obes Rep2019;8:229-42

[113] Abenavoli L,Colica C.Gut microbiota and obesity: a role for probiotics.Nutrients2019;11:2690 PMCID:PMC6893459

[114] Aoun A,Hamod N.The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and synbiotics for weight loss.Prev Nutr Food Sci2020;25:113-23 PMCID:PMC7333005

[115] Gomes AC,Mota JF.The human gut microbiota: metabolism and perspective in obesity.Gut Microbes2018;9:308-25 PMCID:PMC6219651

[116] Turnbaugh PJ,Fulton L.Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome.Cell Host Microbe2008;3:213-23 PMCID:PMC3687783

[117] Weiss GA.Mechanisms and consequences of intestinal dysbiosis.Cell Mol Life Sci2017;74:2959-77

[118] Chatelier E, Nielsen T, Qin J, et al; MetaHIT consortium. Richness of human gut microbiome correlates with metabolic markers.Nature2013;500:541-6

[119] Ley RE,Klein S.Microbial ecology: human gut microbes associated with obesity.Nature2006;444:1022-3

[120] Lau LHS.Microbiota, obesity and NAFLD.Adv Exp Med Biol2018;1061:111-25

[121] Leung C,Furness JB.The role of the gut microbiota in NAFLD.Nat Rev Gastroenterol Hepatol2016;13:412-25

[122] Brandi G,Candela M.Microbiota, NASH, HCC and the potential role of probiotics.Carcinogenesis2017;38:231-40

[123] Yoshimoto S,Atarashi K.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.Nature2013;499:97-101

[124] Wu L,Li J.The gut microbiome-bile acid axis in hepatocarcinogenesis.Biomed Pharmacother2021;133:111036

[125] Ðanić M,Pavlović N.Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome.Front Pharmacol2018;9:1382 PMCID:PMC6287190

[126] Han CY.Update on FXR biology: promising therapeutic target?.Int J Mol Sci2018;19:2069 PMCID:PMC6073382

[127] Jiao Y,Li XY.Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis.Acta Pharmacol Sin2015;36:44-50 PMCID:PMC4571315

[128] Ryan KK,Clemmensen C.FXR is a molecular target for the effects of vertical sleeve gastrectomy.Nature2014;509:183-8 PMCID:PMC4016120

[129] Su H,Liu J.Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma.Am J Physiol Gastrointest Liver Physiol2012;303:G1245-53 PMCID:PMC3532459

[130] Wolfe A,Edwards G,Guo GL.Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice.J Pharmacol Exp Ther2011;338:12-21 PMCID:PMC3126651

[131] Takahashi S,Fukami T.Role of farnesoid X receptor and bile acids in hepatic tumor development.Hepatol Commun2018;2:1567-82 PMCID:PMC6287584

[132] Bosman FT,Hruban RH. WHO classification of tumours of the digestive system. 4th ed. Geneva: World Health Organization; 2010.

[133] Lokuhetty D. Organisation mondiale de la santé, Centre international de recherche sur le cancer. WHO classification of tumours. https://whobluebooks.iarc.fr/ [Last accessed on 17 Jan 2021]

[134] Salomao M,Brown RS Jr,Lefkowitch JH.Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.Am J Surg Pathol2010;34:1630-6

[135] Salomao M,Vaughan R,Lefkowitch JH.The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis.Hum Pathol2012;43:737-46

[136] Shibahara J,Sakamoto Y,Fukayama M.Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients.Histopathology2014;64:951-62

[137] Qin J,Nakagawa S.Steatohepatitic variant of hepatocellular carcinoma is associated with both alcoholic steatohepatitis and nonalcoholic steatohepatitis: a study of 2 cohorts with molecular insights.Am J Surg Pathol2020;44:1406-12 PMCID:PMC7942811

[138] Lee JS,Kim H.Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma.PLoS One2017;12:e0171922 PMCID:PMC5342190

[139] Calderaro J,Imbeaud S.Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.J Hepatol2017;67:727-38

[140] Ziol M,Amaddeo G.Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance.Hepatology2018;68:103-12

[141] Reddy SK,Chen HW.Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.Hepatology2012;55:1809-19

[142] Sanyal A,Moyneur E.Population-based risk factors and resource utilization for HCC: US perspective.Curr Med Res Opin2010;26:2183-91

[143] Pelusi S,Rametta R.Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis.Clin Gastroenterol Hepatol2019;17:2310-9.e6

[144] Petersen KF,Befroy D,Hendler RE.Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.Diabetes2005;54:603-8 PMCID:PMC2995496

[145] Promrat K,Niemeier HM.Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.Hepatology2010;51:121-9 PMCID:PMC2799538

[146] Vilar-Gomez E,Calzadilla-Bertot L.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology2015;149:367-78.e5; quiz e14

[147] Turati F,Polesel J.Mediterranean diet and hepatocellular carcinoma.J Hepatol2014;60:606-11

[148] Gepner Y,Komy O.The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content.J Hepatol2019;71:379-88

[149] EPIC - European Prospective Investigation into Cancer and Nutrition. https://epic.iarc.fr/ [Last accessed on 17 Jan 2021]

[150] Lee Y,Yu J.Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2019;17:1040-60.e11

[151] Mattar SG,Rabinovitz M.Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.Ann Surg2005;242:610-7; discussion 618 PMCID:PMC1402345

[152] Lassailly G,Buob D.Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients.Gastroenterology2015;149:379-88; quiz e15

[153] Lassailly G,Ntandja-Wandji LC.Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis.Gastroenterology2020;159:1290-301.e5

[154] Kwak M,Hawkins RB,Schirmer B.Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: a propensity matched analysis.Am J Surg2020;219:504-7

[155] Malehmir M,Gallage S.Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.Nat Med2019;25:641-55

[156] Beloribi-Djefaflia S,Guillaumond F.Lipid metabolic reprogramming in cancer cells.Oncogenesis2016;5:e189 PMCID:PMC4728678

[157] Foderà D,Cusimano A.Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors.Ann N Y Acad Sci2004;1028:440-9

[158] Kern MA,Sahi D.Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.Hepatology2002;36:885-94

[159] Chen H,Chu ESH.Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice.Oncogene2017;36:4415-26 PMCID:PMC5543258

[160] Simon TG,Aleman S,Chan AT.Association of aspirin with hepatocellular carcinoma and liver-related mortality.N Engl J Med2020;382:1018-28 PMCID:PMC7317648

[161] Huang MY,Chang WK.The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan.Am J Cancer Res2017;7:1606-16 PMCID:PMC5523039

[162] Donadon V,Mas MD,Zanette G.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.Liver Int2010;30:750-8

[163] Hassan M,Kaseb A.Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.Cancer2010;116:1938-46 PMCID:PMC4123320

[164] Bosetti C,Nicotra F.Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.Pharmacoepidemiol Drug Saf2015;24:771-8

[165] Kasmari AJ,Liu G,McGarrity T.Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome.Am J Med2017;130:746.e1-7

[166] Miele L,Turati F.Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk.Gastroenterol Res Pract2015;2015:570356 PMCID:PMC4444581

[167] Zheng L,Wu F.Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.Clin Cancer Res2013;19:5372-80

[168] Cunha V,Rocha R,Lins-Kusterer L.Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review.Ann Hepatol2020;19:232-7

[169] Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012;56:908-43

[170] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2012;379:1245-55

[171] Cauchy F,Dokmak S.Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome.Br J Surg2013;100:113-21

[172] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[173] Howell J,Mannan B,sharma R.Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study.JCO2021;39:289

[174] Jian C,Cheng X.Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis.Cell Metab2020;31:892-908.e11

[175] Bruix J,Merle P.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[176] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[177] Zhu AX,Yen C.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:282-96

[178] Abou-Alfa GK,Cheng AL.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:PMC7523244

[179] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[180] Galle PR,Qin S.Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).JCO2020;38:476

[181] Gordan JD,Abou-Alfa GK.Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline.J Clin Oncol2020;38:4317-45

[182] Rakhra K,Zabuawala T.CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.Cancer Cell2010;18:485-98 PMCID:PMC2991103

[183] Ma C,Eggert T.NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.Nature2016;531:253-7 PMCID:PMC4786464

[184] Pinter M,Peck-Radosavljevic M.Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.Gut2021;70:204-14 PMCID:PMC7788203

[185] Yau T,Finn R.CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).Ann Oncol2019;30:v874-5

[186] Heinrich B,Vormehr M.Abstract 1728: Nonalcoholic steatohepatitis (NASH) impairs treatment of intrahepatic metastases with CD4 + T cell dependent RNA vaccine.Cancer Res2018;78:1728

[187] Artaç M,Coşkun HŞ.Bevacuzimab may be less effective in obese metastatic colorectal cancer patients.J Gastrointest Cancer2019;50:214-20

[188] Guiu B,Bonnetain F.Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.Gut2010;59:341-7

[189] Aparicio T,Faroux R.for FFCD investigatorsOverweight is associated to a better prognosis in metastatic colorectal cancer: a pooled analysis of FFCD trials.Eur J Cancer2018;98:1-9